CRISPR Therapeutics AG
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.5 | $37.3 | $371.2 | $1.2 | $915.0 |
| Operating income | -$664.6 | -$466.6 | -$222.5 | -$673.2 | $373.5 |
| Net income | -$581.6 | -$366.3 | -$153.6 | -$650.2 | $377.7 |
| Cash Flow Statement | |||||
| Free cash flow | -$345.9 | -$144.7 | -$269.8 | -$532.9 | $457.3 |
Shares outstanding 96.7M · Free float 81.7%
Annual filing data through FY ended December 31, 2025; float as of October 3, 2026.